January 5, 2022
On Tuesday, Washington State legislators filed SB 5660, a bill that would legalize the supported adult use of psilocybin by people 21 years of age and older. [The bill] includes, among others, a program to help address harms caused by the war on drugs, a provision to support small businesses, and accommodations for people to receive the psychedelic substance at home.
Full articleDecember 24, 2021
After 2½ years of advocacy and a multitude of letters to local government officials, the Port Townsend Psychedelic Society was rewarded this week. In a unanimous vote, the Port Townsend, Washington City Council adopted a resolution making the arrest of adults possessing psilocybin mushrooms, mescaline and other entheogens a low priority for the police.
Full articleDecember 6, 2021
Stephen Jurvetson, co-founder of Future Ventures and a board member at SpaceX, told me in a one-on-one outside the conference’s lecture hall that he’s a true believer in the industry’s mission to fix the state of mental-health care. So much so, in fact, that he decided last week to carve up his own estate by giving around half of his net worth to fund psychedelic science.
Full articleDecember 4, 2021
n 2019, the FDA made a groundbreaking decision to approve a form of ketamine as a clinical treatment for patients suffering from treatment-resistant depression, a condition which is estimated to affect nearly three million Americans. The drug, called Spravato, is the first psychedelic drug to be approved for the treatment of mental illness. This approval, along with large-scale clinical trials of LSD, MDMA, and psilocybin...
Full articleNovember 29, 2021
Atai bought another 619,095 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%. The new shares were bought at around $31 each, meaning Atai paid around $12 million in total. Atai is planning to increase its stake in Compass Pathways to 29% in the coming weeks, according to a source close to the companies.
Full article